188比分直播排球

188比分网app

Home/Investors/ Press Releases

188比分网app

  • Company Information
  • Financial Information
  • Stock Data
  • Analyst Coverage
  • SEC Filings
  • Corporate Governance
    • 5Nov

    CymaBay Reports Third Quarter 2020 Financial Results and Provides Corporate Update188比分网app

    5Nov

    CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes188比分网app

    2Nov

    CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020188比分网app

    30Oct

    CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020188比分网app

    1Oct

    CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting® 2020188比分网app

    3Sep

    CymaBay Therapeutics to Present at Upcoming Investor Conferences188比分网app

    27Aug

    CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress™ 2020188比分网app

    20Aug

    CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020188比分网app

    10Aug

    CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update188比分网app

    3Aug

    CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020188比分网app

    RSS
    Show All

    188比分网app

    • 7575 Gateway Blvd., Suite 110
      Newark, CA 94560
    • +1 (510) 293-8800
    • +1 (510) 293-9090

    188比分网app

    188比分网app

    1818彩票官方网站188比分直播app下载ios188足球比分最新优惠18彩票2018彩票网1997香港官方彩票